Last reviewed · How we verify
Beijing Shenogen Biomedical Co., Ltd — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Sorafenib Tosylate Tablets | Sorafenib Tosylate Tablets | phase 3 | multi-kinase inhibitor | RAF kinase, VEGFR, PDGFR | Oncology | |
| HUACHANSU PIAN | HUACHANSU PIAN | phase 3 | Traditional Chinese medicine extract; natural product | Oncology |
Therapeutic area mix
- Oncology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Technical University of Munich · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Beijing Shenogen Biomedical Co., Ltd:
- Beijing Shenogen Biomedical Co., Ltd pipeline updates — RSS
- Beijing Shenogen Biomedical Co., Ltd pipeline updates — Atom
- Beijing Shenogen Biomedical Co., Ltd pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Beijing Shenogen Biomedical Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beijing-shenogen-biomedical-co-ltd. Accessed 2026-05-16.